Ann: Imugene successfully completes preclinical animal studies-IMU.AX, page-6

Hi Mr B

Possibly you are unaware that there has already been a Phase 1a trial in humans - with excellent results. The new formulation of Her-Vaxx is, however, much more powerful and therefore required toxicology testing on non-human subjects.

The Charles River labs are highly reputable. I'm not quite sure why you are concerned that the testing was in rats and beagles. Would you prefer mice and poodles?

There are of course many biotech research targets closer to commercialisation than Her-Vaxx - you bet. Then again, they generally have a share price to match. So if you are happy to pay a premium for a shorter run up and less risk, with less potential % gain - go for it. No need need to stick around here being bored.

I'm not betting the farm on Imugene, but the risk/reward potential suits me for the amount I have invested, and I'm prepared to wait through the research and see what happens. If you want an investment with a rapid result, you should certainly be looking elsewhere.

Cheers

Dave